Audit of safety and quality of the use of enoxaparin for anticoagulation in continuous renal replacement therapy

Critical Care and Resuscitation

Volumn 13, Issue 1, 2011, Pages 24-27

  Tsang, David J ^a   Tuckfield, Annabel ^a   MacIsaac, Christopher M ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN;

ADULT; AGED; APACHE; ARTICLE; COMPARATIVE STUDY; EVALUATION; HEMOFILTRATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; LENGTH OF STAY; MALE; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APACHE; ENOXAPARIN; HEMOFILTRATION; HUMANS; INTENSIVE CARE UNITS; KIDNEY DISEASES; LENGTH OF STAY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; TIME FACTORS;

EID: 79953749717     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Brophy PD, Somers MJ, Baum MA, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 2005; 20: 1416-21.
2. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006; 32: 188-202.
3. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-7.
4. Reeves JH, Cumming AR, Gallagher L, et al. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med 1999; 27: 2224-8.
5. Joannidis M, Kountchev J, Rauchenzauner M, et al. Enoxaparin vs unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. Intensive Care Med 2007; 33: 1571-9.
6. Hirsh J, Warkentin TE, Raschke R, et al. Heparin and low-molecularweight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (5 Suppl): 489S-510S.
7. Isla A, Gascon AR, Maynar J, et al. In vitro and in vivo evaluation of enoxaparin removal by continuous renal replacement therapies with acrylonitrile and polysulfone membranes. Clin Ther 2005; 27: 1444-51.
8. Singer M, McNally T, Screaton G, et al. Heparin clearance during continuous veno-venous haemofiltration. Intensive Care Med 1994; 20: 212-5.
9. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
10. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 1991; 100: 1619-36.
11. Buller HR, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 401S-28S.